Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Novara – page 194

2 684 clinical trials in Novara, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Novara at a glance
2 684
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 684 trials in Novara

Open in trial search

Chronic myeloid leukaemia

Not recruiting

Comparison of nilotinib versus imatinib treatment in newly diagnosed chronic myeloid leukemia patients to achieve treatment-free remission

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

General anaesthesia

Not recruiting

Study on the Effects of Low-Dose Sevoflurane, Dexmedetomidine, and Remifentanil Anesthesia on Neurodevelopment in Children Under 2 Undergoing Long Surgeries

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Sevoflurane
  • Sponsor:IRCCS Istituto Giannina Gaslini

Malignant melanoma stage III

Not recruiting

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

HIV infection

Not recruiting

Study Comparing Bictegravir/Lenacapavir to Current Therapy in People with HIV-1 Who Are Successfully Treated

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Duchenne muscular dystrophy

Not recruiting

Study of DYNE-251 safety and effectiveness in patients with Duchenne muscular dystrophy who are candidates for exon 51 skipping treatment

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Sponsor:Dyne Therapeutics Inc.

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Arteriovenous graft thrombosis

Not recruiting

Study on MK-2060 for Preventing Blood Clots in Dialysis Patients with End-Stage Kidney Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MK-2060
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer stage III

Not recruiting

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

HER2 positive breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Prostate cancer metastatic

Not recruiting

Study of enzalutamide alone versus enzalutamide with radium-223 combination in patients with bone metastatic castration-resistant prostate cancer with mild or no symptoms

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:European Organisation For Research And Treatment Of Cancer

HER2 mutant non-small cell lung cancer

Not recruiting

Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Novara

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on hematologic malignancies and solid tumors, investigating innovative treatments for various cancer types including leukemia, breast cancer, and lung cancer.

  • Advanced breast cancer therapies
  • Chronic myeloid leukemia treatments
  • Non-small cell lung cancer interventions

Studies evaluating combination therapies and targeted treatments to improve patient outcomes.

02 Cardiovascular Studies

Research focusing on heart failure prevention and treatment strategies, particularly exploring new drug combinations and their impact on cardiovascular outcomes.

  • Heart failure risk reduction
  • Cardiovascular death prevention
  • Chronic kidney disease management

Innovative approaches combining multiple therapeutic agents to address cardiovascular risks.

03 Autoimmune Conditions

Investigations into treatments for various autoimmune disorders, including Sjögren's Syndrome and rheumatoid arthritis, with emphasis on novel therapeutic approaches.

  • Biomarker-guided treatments
  • Long-term safety evaluations
  • Innovative therapeutic combinations

Focus on developing targeted therapies for better disease management and patient care.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.